PharmExec Blog
Follow Us
RSS
Bookstore
Author Archives: William Looney
PCORI, Priorities, and Politics
William Looney looks at the three P’s of effectiveness research: PCORI, Priorities, and Politics
If you ever wanted to know what health economists might do with a billion dollars, the Obama Administration’s Patient-Centered Outcomes Research Institute [PCORI] is about to tell all: not right down to the penny, but good enough. The congressionally funded – [...]
Calculating the Cost of R&D: Defending Tufts Research
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price?
Posted in Op-Ed, R&D, pricing Tagged Donald Light, Ken Kaitin, productivity lag, R&D, Rebecca Warbuton, Tufts Center for the Study of Drug Development 1 Comment
The Seven-Billion Society: What's In It For Pharma?
On Monday, the world’s population hit the 7 billion mark, repeating a pattern of largely unrestrained growth that has endured for the last century: the world is now adding roughly one billion people every 12 years. The UN Population Fund (UNPF) estimates that, barring some unforeseen demographic or environmental/development shifts, the figure will reach just [...]
Posted in Global, Op-Ed, healthcare Tagged Big Pharma, healthcare, innovation, population, UN 1 Comment
It's Industry's Problem: A Fresh Take on R&D Costs
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty.
If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]
HBA 2012 Woman of the Year: Thinking Beyond the Box